Riskpilot← Back to searchSign inGet full accessNOVARTIS NORGE AS
ASActiveOrg 965599614Nydalsveien 28, 0484 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 199283 employeeswww.novartis.no
Revenue 2024
NOK 1,4B
+8% vs 2023
EBITDA margin
4.1%
+34% vs 2023
Equity ratio
53.7%
Financial strength
Net profit 2024
NOK 42,3M
+32% vs 2023
| Revenue | NOK 1,4B | +8% |
| EBITDA | NOK 56,3M | +34% |
| Net profit | NOK 42,3M | +32% |
| Total assets | NOK 619,7M | +25% |
| Equity | NOK 332,6M | +15% |
| Employees | 83 | — |
Legal name
NOVARTIS NORGE AS
Org number
965599614
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14. september 1992
Share capital
—
Employees
83 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Forskning, utvikling og kommersialisering av legemidler og medisinsk utstyr.
Address
Nydalsveien 28, 0484 Oslo
Phone
+4723052000
Email
media.relations@novartis.com
Website
www.novartis.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 452 692 | 1 423 255 | 1 242 904 | 1 276 257 | 1 378 114 |
| Staff expenses | −160 896 | −147 397 | −196 853 | −147 901 | −0 |
| EBITDA | 54 927 | 59 369 | 39 660 | 42 125 | 56 286 |
| Depreciation & amort. | −886 | −556 | −626 | −648 | −866 |
| EBIT | 54 042 | 58 813 | 39 034 | 41 477 | 55 420 |
| Net financials | −2 016 | −648 | −360 | −373 | −1 322 |
| Profit before tax | 52 026 | 58 165 | 38 673 | 41 104 | 54 097 |
| Tax | 11 705 | 12 986 | 8 610 | 9 146 | −0 |
| Net profit | 40 321 | 45 179 | 30 063 | 31 958 | 42 338 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 500 313 | 442 290 | 592 491 | 496 675 | 619 699 |
| Equity | 183 109 | 228 289 | 258 352 | 290 310 | 332 648 |
| Long-term debt | 50 000 | 0 | 0 | 1 654 | 12 464 |
| Short-term debt | 266 799 | 213 552 | 333 794 | 204 435 | 273 183 |
| Total debt | 316 799 | 213 552 | 333 794 | 206 089 | 285 647 |
EBITDA margin
4.1%
This company
15.8%
Market median
-74% vs market
20202024
Equity ratio
53.7%
This company
38.2%
Market median
+41% vs market
20202024
Return on equity
12.7%
This company
18.4%
Market median
+31% vs market
20202024
Net profit margin
3.1%
This company
8.1%
Market median
-62% vs market
20202024
Asset turnover
2.22×
This company
1.12×
Market median
+98% vs market
20202024
Debt / equity
0.86×
This company
0.62×
Market median
+39% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
VB Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2025 | |
| Board of Directors | 2025 | |
| Former (4) | ||
| Chairman | 2022 – 2025 | |
| Chairman | 2022 – 2022 | |
| Chairman | 2020 – 2022 | |
| Board of Directors | 2022 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Novartis Holding Ag | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NOVARTIS NORGE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Veronika Barrabès | Chief Executive Officer | 0 companies |
| Johan Mikael Olof Kahlström | Chairman | 0 companies |
| Geir Roger Høli | Chairman | 0 companies |
| Frances Clare Milnes | Chairman | 0 companies |
| Judith Louise Love | Chairman | 0 companies |
| René Kristoffersen | Board of Directors | 0 companies |
| Rolf Thomas Rønning | Board of Directors | 0 companies |